Alpha-9 Theranostics - About the company
Alpha-9 Theranostics is a series B company based in Vancouver (Canada), founded in 2019. It operates as a Developer of molecules for solid and hematologic malignancies. Alpha-9 Theranostics has raised $83.9M in funding from Longitude Capital and Nextech Invest. The company has 2604 active competitors, including 894 funded and 644 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.
Company Details
Developer of molecules for solid and hematologic malignancies. It offers peptide-based radiopharmaceuticals iwhich includes prostate specific membrane antigen, prostate specific membrane antigen, C-X-C chemokine receptor type 4, bradykinin B1 receptor and others for therapeutic and diagnostic purpose.
Key Metrics
Founded Year
2019
Location
Vancouver, Canada
Stage
Series B
Total Funding
$83.9M in 2 rounds
Latest Funding Round
Investors
Ranked
773rd among 2604 active competitors
Employee Count
40 as on Aug 31, 2026
Similar Companies
Sign up to download Alpha-9 Theranostics' company profile
Alpha-9 Theranostics's funding and investors
Alpha-9 Theranostics has raised a total funding of $83.9M over 2 rounds. Its first funding round was on Apr 28, 2021. Its latest funding round was a Series B round on Dec 14, 2022 for $*****. 6 investors participated in its latest round. Alpha-9 Theranostics has 7 institutional investors.
Here is the list of recent funding rounds of Alpha-9 Theranostics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Dec 14, 2022 | 5607576 | Series B | 9073891 | 9735964 | 7381827 | 6365630 |
Apr 28, 2021 | 8212184 | Series A | 7492270 | 4066640 |
Access funding benchmarks and valuations. Sign up today!View details of Alpha-9 Theranostics's funding rounds and investors
Alpha-9 Theranostics' founders and board of directors
Founder? Claim ProfileAlpha-9 Theranostics' employee count trend
Alpha-9 Theranostics has 40 employees as of Aug 26. Here is Alpha-9 Theranostics's employee count trend over the years:
Uncover Alpha-9 Theranostics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Alpha-9 Theranostics's Competitors and alternates
Top competitors of Alpha-9 Theranostics include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Alpha-9 Theranostics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 73/100 | |
3rd | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
4th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
5th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
6th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 71/100 | ||
7th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
8th | _1545299782322.png?devicePixelRatio=2&height=30&width=30){kind=logo} Erasca 2018, San Diego (United States), Public | Developer of small molecule based therapeutics for cancer | $300M | 71/100 | |
9th |  Elicio 2012, Cambridge (United States), Public | Developer of vaccines for treating cancer | $47.4M | 71/100 | |
10th | Celularity 2016, Warren (United States), Public | Developer of allogeneic cell therapies to treat multiple diseases | $290M | 71/100 | |
773rd |  Alpha-9 Theranostics 2019, Vancouver (Canada), Series B | Developer of molecules for solid and hematologic malignancies | $83.9M | 55/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Alpha-9 Theranostics's competitors? Click here to see the top ones
Alpha-9 Theranostics's Investments and acquisitions
Alpha-9 Theranostics has made no investments or acquisitions yet.
Reports related to Alpha-9 Theranostics
Here is the latest report on Alpha-9 Theranostics's sector:
News related to Alpha-9 Theranostics
Media has covered Alpha-9 Theranostics for a total of 2 events in the last 1 year, 1 of them has been about company updates and 1 about people movement.
•
•
Alpha-9 Oncology Appoints Paul Blanchfield as Chief Executive Officer - AlphaAlpha-9 Oncology•Nov 10, 2025•Alpha-9 Theranostics
•
•
•
•
•
•
•
Targeted radiotherapy biotech out of Longitude Capital raises a fresh $75MEndPoints News•Dec 14, 2022•Alpha-9 Theranostics, Longitude Capital, Nextech Invest, Frazier Healthcare Partners and 2 others
•
Alpha-9 Theranostics Announces $11 Million Series A Financing to Advance Portfolio of Radiotherapeutics and DiagnosticsAlpha-9 Oncology•Apr 28, 2021•Alpha-9 Oncology, Longitude Capital, BVF Partners, Alpha-9 Theranostics and 1 other
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Alpha-9 Theranostics
Explore our recently published companies
- Bernierobbins - Unfunded company
- Baronhats - United States based, Unfunded company
- Nivmeh - 2023 founded, Unfunded company
- eldoLED - United States based, 2005 founded, Unfunded company
- Right E-Waste Recycle - Unfunded company
- Connect Info Solutions - Mumbai based, 2012 founded, Unfunded company
